GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Long-Term Debt & Capital Lease Obligation

PhaseRx (PhaseRx) Long-Term Debt & Capital Lease Obligation : $3.61 Mil (As of Sep. 2017)


View and export this data going back to 2016. Start your Free Trial

What is PhaseRx Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. PhaseRx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $3.61 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. PhaseRx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2017 was $3.61 Mil. PhaseRx's Total Assets for the quarter that ended in Sep. 2017 was $6.04 Mil. PhaseRx's LT-Debt-to-Total-Asset for the quarter that ended in Sep. 2017 was 0.60.

PhaseRx's LT-Debt-to-Total-Asset increased from Sep. 2016 (0.29) to Sep. 2017 (0.60). It may suggest that PhaseRx is progressively becoming more dependent on debt to grow their business.


PhaseRx Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for PhaseRx's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseRx Long-Term Debt & Capital Lease Obligation Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
Long-Term Debt & Capital Lease Obligation
- - 5.13

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.61 5.13 4.65 4.14 3.61

PhaseRx Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


PhaseRx  (OTCPK:PZRXQ) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PhaseRx's LT-Debt-to-Total-Asset ratio for the quarter that ended in Sep. 2017 is calculated as:

LT-Debt-to-Total-Asset (Q: Sep. 2017 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2017 )/Total Assets (Q: Sep. 2017 )
=3.611/6.038
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


PhaseRx Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of PhaseRx's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseRx (PhaseRx) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Long-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
N/A
Address
410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Executives
Gordon Brandt officer: Chief Medical Officer 410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr director 300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio 10-13-2017

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm 05-24-2016